SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The indication for PCI was chronic stable angina in 46.1% (n=26), non-ST elevation acute coronary syndrome (NSTEACS) in 33.3% (n=18) and ST-elevation myocardial infarction (STEMI) in 18.5% (n=10) of patients.
|
31130523 |
2020 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management.
|
30117751 |
2020 |
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From 434,172 low-risk, uncomplicated ACS patients eligible for early discharge (STEMI 35%, UA/NSTEMI 65%) from the Premier database, we identified ACS care pathways, by stratifying low-risk, uncomplicated STEMI and UA/NSTEMI patients by access site for PCI (trans-radial intervention [TRI] vs transfemoral intervention [TFI]) and by length of stay (LOS).
|
31812224 |
2020 |
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
US respondents used TRA less commonly for primary PCI for STEMI than their global counterparts.
|
30456913 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This highlights the persistently dramatic impact of SCA on STEMI and the major importance of PCI in this setting.
|
30608874 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to discuss the efficacy and safety of the application of thrombus aspiration catheters during emergency PCI operations for acute ST-elevation myocardial infarction (STEMI) patients with high thrombus load.
|
31547844 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognosis and first diagnostic ECG in STEMI patients referred to the emergency medical system for primary PCI.
|
30497744 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Left Ventricular Thrombus After Primary PCI for ST-Elevation Myocardial Infarction: 1-Year Clinical Outcomes.
|
30871923 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated whether the metabolomic analysis could identify a specific fingerprint of coronary blood collected during primary PCI in STEMI patients.
|
30670713 |
2019 |
SERPINA5
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with STEMI undergoing primary PCI were recruited.
|
31771514 |
2019 |
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred seventeen patients with STEMI and undergoing pPCI were randomly divided into the sustained nicorandil group (5 mg, three times daily) or the control group (only single nicorandil before PCI).
|
30821716 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background We hypothesized that female sex is a treatment effect modifier of blood flow and related 30-day mortality after primary percutaneous coronary intervention ( PCI ) for ST -segment-elevation myocardial infarction and that the magnitude of the effect on outcomes differs depending on delay to hospital presentation.
|
30764687 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Late delayed PCI (14-28 days) after STEMI was associated with a higher incidence of in-hospital adverse events particularly in women and smokers but not with Killip class II-III heart failure, which might allow medical treatment to improve function.
|
31737517 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to evaluate outcomes on the basis of P2Y12 inhibitor therapy in patients from the Thrombectomy With PCI Versus PCI Alone in Patients With STEMI Undergoing Primary PCI (TOTAL) trial.
|
31492492 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI.
|
30464124 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to compare delayed PCI and medication therapy beyond the recommended time window of 12 h after the onset of symptoms on the outcomes of STEMI patients.
|
31772517 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess whether T<sub>peak</sub>-T<sub>end</sub> before PCI in STEMI is associated with reperfusion VF.
|
30661844 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the infarct size and in-hospital mortality in STEMI patients with negative T wave in cases of primary PCI strategy compared with conservative treatment.
|
31368226 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Time-dependent benefits of pre-treatment with new oral P2Y<sub>12</sub> -inhibitors in patients addressed to primary PCI for acute ST-elevation myocardial infarction.
|
30269413 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quality of care indicators were identified in terms of emergency timeliness (time between residence and the nearest hospital), hospital performance in treatment of acute phase (number/timeliness of PCI on STEMI) and drug therapy in post-acute phase (number of drugs among antiplatelet, β-blockers, ACE inhibitors/ARBs, statins).
|
30785928 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
There may be a role for initial therapy of STEMI with a broad-spectrum anticoagulant such as heparin that is then focused to a more specific direct-thrombin inhibitor (bivalirudin) in primary PCI.
|
30719862 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Index of Microcirculatory Resistance as a Tool to Characterize Microvascular Obstruction and to Predict Infarct Size Regression in Patients With STEMI Undergoing Primary PCI.
|
29680355 |
2019 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients undergoing p-PCI for STEMI, MEA platelet function observed in coronary arteries was consistent with peripheral artery blood's independently of the antiplatelet drug used.
|
29575927 |
2018 |
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We pooled patients with STEMI discharged on prasugrel in 2 prospective registries (Bern PCI Registry [NCT02241291] and SPUM-ACS (Inflammation and Acute Coronary Syndromes) [NCT01000701]) and 1 STEMI trial (COMFORTABLE-AMI (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction) [NCT00962416]).
|
29654204 |
2018 |